Led · Seed · Apr 2026

Resolv develops an AI-native platform that automates identifying, filing and tracking rebates for home services contractors and integrates with ServiceTitan and Housecall Pro. The company also offers upfront rebate financing so contractors receive payment immediately rather than waiting months for reimbursement. Founded by Sam Ruderman and Shane Smith and based in San Francisco, Resolv began operations in 2025. In 2025 it secured roughly $10M in rebates for nearly 100 contractors in California. The company is expanding its product scope into permits, warranty registrations and broader back-office workflows as it builds a single end-to-end platform. The recent Pre-Seed raise will fund expanded operations and development efforts to support that growth.

Led · Seed · Jan 2026

RouteSense provides a unified intelligence layer that consolidates fragmented payment data across the transaction lifecycle, giving stakeholders near-real-time insight into merchant identification (MID) health. Its debut product, Pathfinder, continuously monitors network-defined health indicators and dynamically routes transactions to the healthiest MIDs, helping merchants maintain authorization performance and comply with Visa’s new Visa Acquiring Monitoring Program (VAMP). Unlike legacy reporting tools that surface issues weeks later, Pathfinder offers predictive analytics that enable proactive intervention before fines or account holds occur. The platform is powered by a modern data infrastructure and is designed to expand across the full payment lifecycle, ultimately becoming the operating intelligence layer for acquirers worldwide. RouteSense was founded by industry veterans Stephen Martin, Robert Matthews, and Colin Martin, who collectively bring more than 75 years of payments and real-time analytics experience. The company is currently onboarding select merchants, payment service providers, and processors. Future plans include adding continuous portfolio visibility, predictive risk signals, and end-to-end MID health management capabilities.

Participated · Seed · Sep 2025

Trially AI has built a fully integrated, HIPAA-compliant platform that tackles the biggest bottleneck in clinical research—patient recruitment. Its core products include Trially Match, which analyzes unstructured EHR data to find eligible participants; Trially Connect, where the new agentic AI assistant “Margo” engages and pre-screens those candidates; and Trially Intelligence, a pipeline radar that flags suitable trials for a given patient population. The system can identify patients with roughly 95% screening accuracy, enroll 2–6× more patients per month in complex trials, reduce screen failures by 73%, and cut manual chart-review time by 91%. One research site network reported a $4 million revenue increase within three months of deployment, and users see as much as a 10× jump in identified trial candidates. The company positions itself for physicians, research sites, CROs, and pharmaceutical sponsors needing faster, more diverse enrollment. With fresh seed funding, management plans to accelerate platform adoption across research sites, sponsors, CROs, and physician networks. Financially, Trially AI has secured $4.7 million in seed capital to fuel this next phase of growth.

Participated · Seed · Jul 2025

Asepha develops a stack of interoperable AI agents that streamline pharmacy workflows and reduce administrative burden. Its product suite includes an OCR prescription-entry agent with 96% accuracy, a call agent that automates up to 70% of inbound phone calls, and a browser-navigation agent for real-time web tasks. Validation experiments found pharmacists preferred Asepha’s AI responses over a human pharmacist’s responses 71% of the time in a double-blinded randomized trial. The company targets pharmacies facing acute staffing shortages—about 70% of pharmacies are understaffed and pharmacists spend as much as 90% of their time on analog administrative work. Asepha has secured multiple Fortune 50 enterprise customers, demonstrating early commercial traction. With the new funding it plans to grow engineering and go-to-market teams, expand global partnerships, and increase its U.S. footprint with a New York City office.

Participated · Seed · Mar 2025

Synvect is a San Diego-based biotech company founded by scientists from UC San Diego that develops CRISPR-based mosquito suppression technology. Its core product uses CRISPR to create sterile male mosquitoes that mate with wild females to prevent reproduction, a method designed to remain contained and avoid gene drives. The company has received U.S. EPA approval for its first product, SEPARATOR, and is launching pilot programs with government and mosquito control agencies in Florida, Texas, California, and other high-risk regions. Synvect’s approach is positioned as an eco-friendly alternative to chemical pesticides and seeks large-scale deployment to combat rising mosquito-borne diseases. The company is built on 15 years of research and has previously received $20M in prior funding. The recent financing will accelerate development, regulatory engagement, and commercial roll-out in collaboration with government agencies, researchers, and communities.